COMPASS Pathways
Psychedelics research for mental healthcare
- 101-200 employees
- Healthcare
- Enterprise
- Mental health
- Wellbeing
- Science
- Biotechnology
- Soho, London, UK
Jump to section
Company mission
COMPASS Pathways' mission is to accelerate patient access and experience to evidence-based innovation in mental health care, to achieve a vision of a world of mental wellbeing.
Our take
There’s been a major movement towards treating mental health issues with psychedelics over the last few years. While the vast majority of this work is still in R&D and clinical trials, the space has become awash with capital investment, with a handful of companies even going public.
COMPASS Pathways is one of those to go public, along with MindMed in 2020. The company is developing methods for treating depression and other mental health issues with psilocybin – the naturally occurring psychedelic chemical found in mushrooms.
The growth of COMPASS from being founded in 2016 to IPO in 2020 has been extraordinary. There have been a few ups and downs since then (as is the case with most PLCs), with each rise and fall dependent on the progress of its trials. However, the fact that the company recently appointed former Otsuka Pharmaceutical executive Kabir Nath as CEO, bolstered by $285 million in private placement VC shows that it's determined to stay ahead of the competition.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Hybrid working
- Generous paid time off/annual leave allowance including two company closings per year and your birthday off
- Comprehensive and market-leading health and wellness benefits including medical and dental insurance, and wellness rewards
- Confidential counselling or therapy sessions
- Mental Health First Aid training
- Support from our own dedicated wellbeing concierge to guide team members to all of our resources
- Employee-led yoga, meditation and wellbeing support groups
- Highly competitive base pay, bonus and equity participation programmes
- Pension and retirement benefits
- Substantial individual annual learning and development allowance
Funding (last 2 of 3 rounds)
Apr 2020
$80m
SERIES B
Oct 2018
$25m
SERIES A
Total funding: $109.1m
This company has top investors
Leadership
Kabir Nath
(CEO, not founder)Joined as CEO in 2022, having served as Senior Managing Director of Global Pharmaceutical Business at Japanese company Otsuka. Prior to this they spent a decade at Bristol Myers Squibb in a number of roles including SVP of Virology, US Pharmaceuticals.
Ekaterina Malievskaia MD
(Co-founder & Chief Innovation Officer)Physician with a Medical Degree from St Petersburg Medical Academy, Russia. Was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, and a Research Professor at City University of New York. Later moved to London to work in mental healthcare and co-found COMPASS Pathways with husband George Goldsmith.
George Goldsmith
(Co-founder & Executive Chairman)Former senior advisor at McKinsey & Company’s leadership, later joining the company as CEO of TomorrowLab. Founded Tapestry Network in 2002, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. Spent 20 years as CEO, now serving as Non-Executive Chairman..